Anacor's AN2728, AN2898 Meet Endpoints In state of matter 2a Study In Atopic Dermatitis RTT News ... in atopic dermatitis in 2012 will materially affect the company's previously explicit ability to complete its two Phase 3 trials for tavaborole in onychomycosis and its first state of matter 3 trial for AN2728 in psoriasis with its current financial resources. ... Anacor Pharmaceuticals Announces affirmative Preliminary Results from state of matter 2a ... MarketWatch (press release) all 13 tidings articles » Link To Article
No comments:
Post a Comment